Journals / Turkish Journal of Gastroenterology / 2019 / Cilt: 30 - Sayı: 4

Effects of synbiotic therapy in mild-to-moderately active ulcerative colitis: A randomized placebo-controlled study

Pages
313–320
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Background/Aims: Recently, there has been an increasing interest in the effects of probiotics and prebiotics on ulcerative colitis (UC).In the present study, we aimed to evaluate the effect of synbiotic therapy on the clinical and endoscopic activities of the disease in patients with mild-to-moderately active UC.Materials and Methods: Overall, 40 patients with mild-to-moderate UC activity were included in the study and were randomized to thesynbiotic and control groups.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aims: Recently, there has been an increasing interest in the effects of probiotics and prebiotics on ulcerative colitis (UC).In the present study, we aimed to evaluate the effect of synbiotic therapy on the clinical and endoscopic activities of the disease in patients with mild-to-moderately active UC.Materials and Methods: Overall, 40 patients with mild-to-moderate UC activity were included in the study and were randomized to thesynbiotic and control groups.
📊
Key Findings & Data:Synbiotic therapy was administered in the synbiotic group and placebo was administered in the controlgroup for 8 weeks.
💡
Conclusion & Impact:Moreover,although it appears to positively affect the acute phase reactants and endoscopic activity levels, the difference was not significantwhen compared with the patients who did not receive synbiotic therapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background/Aims: Recently, there has been an increasing interest in the effects of probiotics and prebiotics on ulcerative colitis (UC).In the present study, we aimed to evaluate the effect of synbiotic therapy on the clinical and endoscopic activities of the disease in patients with mild-to-moderately active UC.Materials and Methods: Overall, 40 patients with mild-to-moderate UC activity were included in the study and were randomized to thesynbiotic and control groups. Synbiotic therapy was administered in the synbiotic group and placebo was administered in the controlgroup for 8 weeks. Both groups were evaluated and compared in terms of the acute phase reactants and clinical and endoscopic activities of the disease at the beginning and at the end of the 8-week therapy.Results: At the end of the study duration, the decrease in the serum C-reactive protein (CRP) and sedimentation values in the synbioticgroup was statistically significant (p=0.003). In both groups, a statistically significant improvement was observed in the clinical andendoscopic activity levels at the end of the treatment (symbiotic: p=0.001 and p=0.002, respectively; control: p=0.005 and p=0.001,respectively). When the groups were compared with each other, improvement in the clinical activity was significantly higher in the synbiotic group (p<0.05).Conclusion: The use of synbiotic therapy in patients with UC has a significant effect on the improvement in clinical activity. Moreover,although it appears to positively affect the acute phase reactants and endoscopic activity levels, the difference was not significantwhen compared with the patients who did not receive synbiotic therapy.

🔖

Cite This Article

ALTUN, H. K., YILDIZ, E. A., AKIN, M. (2019). Effects of synbiotic therapy in mild-to-moderately active ulcerative colitis: A randomized placebo-controlled study. Turkish Journal of Gastroenterology, Cilt: 30 - Sayı: 4, 313–320. https://ajindex.com/articles/409286

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Judge TA, Lichtenstein GR. Inflammatory Bowel Disease. Friedman SL, McQuaid KR, Grendell JH, editors. CURRENT Diagnosis&Treatment in Gastroenterology. 2th ed. America: McGraw-Hill Companies; 2003. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004; 126: 1504-17. [CrossRef] Osterman MT, Lichtenstein GR. Ulcerative Colitis. Feldman M, Friedman LS, Brandt LJ, editors. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. Canada: Saunders Elsevier; 2010. [CrossRef] Ardizzone S, Bianchi Porro G. Inflammatory bowel disease: new insights into pathogenesis and treatment. J Intern Med 2002; 252: 475-96. [CrossRef] Korkmaz U, Celebi A. İnflamatuvar Barsak Hastalıklarında Beslenme. Şenturk E, editor. İnflamatuvar Barsak Hastalıkları. İstanbul: Epimat Ofset; 2012.
  2. Altun R, Ozden A. İnflamatuvar bağırsak hastalıklarında diyet. Güncel Gastroenteoloji 2014; 18: 440-3.
  3. Kara A, Coskun T. Teoriden Kliniğe Prebiyotikler Probiyotikler. İstanbul: Akademi Uluslararası Yayıncılık San. ve Tic.Ltd.Şti; 2014. Ozden A. İnflamatuvar barsak hastalığında probiyotiklerin yeri. Güncel Gastroenteoloji 2008; Haziran: 122-7. Armonk NY. IBM SPSS Statistics for Windows 22.0 ed: IBM Corp.; 2013.
  4. Cui HH, Chen CL, Wang JD, et al. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol 2004; 10: 1521-5. [CrossRef] Bai AP, Ouyang Q, Xiao XR, Li SF. Probiotics modulate inflammatory cytokine secretion from inflamed mucosa in active ulcerative colitis. Int J Clin Pract 2006; 60: 284-8. [CrossRef] Baroja ML, Kirjavainen SH, Reid G. Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients. British Society for Immunology, Clinical and Experimental Immunology 2007; 149: 470-9. [CrossRef] Hegazy SK, El-Bedewy MM. Effect of probiotics on pro-inflammatory cytokines and NF-kappaB activation in ulcerative colitis. World J Gastroenterol 2010; 16: 4145-51. [CrossRef] Senol A, Isler M, Sutcu R, Akin M, Cakir E, Ceyhan BM, et al. Kefir treatment ameliorates dextran sulfate sodium-induced colitis in rats. World J Gastroenterol 2015; 21: 13020-9. [CrossRef] Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 2005; 54: 242-9. [CrossRef] Fujimori S, Gudis K, Mitsui K, et al. A randomize